Matthew R. Cooperberg, MD, MPH
Matthew R. Cooperberg, MD, MPH
Matthew Cooperberg, MD, MPH received his undergraduate training from Dartmouth College, where he earned a degree in English with high honors. He then enrolled in Yale University's MD, MPH program, concurrently earning an MPH with a concentration in Health Policy from the School of Epidemiology and Public Health, and a MD from the School of Medicine. He completed his General Surgery and Urology training at the University of California, San Francisco, and subsequently continued at UCSF to complete a fellowship in Urologic Oncology under the guidance of Peter Carroll, MD, MPH. In 2009, Dr. Cooperberg was recruited to join the faculty at UCSF and the San Francisco Veterans Affairs Medical Center. Specializing in urologic cancer care, he is part of the multidisciplinary urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center, located primarily at the Mission Bay campus. He also maintains privileges at San Francisco General Hospital. In 2013, Cooperberg received the first Helen Diller Family Chair in Urology and a secondary appointment in the Department of Epidemiology and Biostatistics. In 2015 he won the American Urological Association Gold Cystoscope Award, given annually to one urologist for contributions to the field in the first 10 years of practice.
Dr. Cooperberg's clinical interests include the early detection, diagnosis, and management of genitourinary malignancy, and using minimally invasive techniques to treat benign and malignant diseases. He performs robotic, laparoscopic, endoscopic, and percutaneous surgeries, and is interested in incorporating promising new technologies into his practice. He is particularly interested in risk-stratifying prostate, renal, and other tumors, and matching treatments appropriately to those patients most likely to benefit, using novel imaging tests and biomarkers together with clinical information. Dr. Cooperberg is a Fellow of the American College of Surgeons, and a member of the American Urological Association (AUA) and the Society for Urologic Oncology. In 2012 Dr. Cooperberg co-wrote a proposal to establish a national urology registry. From this proposal developed the AUA Quality (AQUA) Registry, a national database tracking practice patterns, quality of care, and both clinical and patient-reported outcomes for patients across the U.S. with prostate cancer and other urologic conditions.
Drawing on the CaPSURE registry, UCSF’s institutional databases, and other data resources, Dr. Cooperberg has written over 190 peer-reviewed scientific articles, and has been invited to present his research findings at many national and international conferences. His primary research focus is prostate cancer, with particular areas of interest including: 1) health services research, documenting ongoing trends and regional variation in the use of diagnostic, imaging, and therapeutic interventions for men with all stages of prostate cancer; 2) risk assessment, developing and validating prognostic tools incorporating both standard clinical information and emerging biomarkers; 3) comparative effectiveness research, examining evidence regarding the relative benefits of surgery, radiation, and other treatments in terms of cancer control, quality of life, and cost; and 4) decision support and survivorship, helping men make better-informed decisions about both treatments and management of short- and long-term treatment sequelae. He is also very interested in prostate cancer as an international disease, and has helped forge a number of inter-continental collaborations which are yielding fascinating insights into prostate cancer’s variation in presentation and outcome around the world. He has received numerous awards for his research papers and is co-investigator on multiple grants. He won a prestigious Young Investigator Award from the Prostate Cancer Foundation, and is an investigator on a number of ongoing Federal grants.
1825 4th Street
4th floor UCSF Ron Conway Family Gateway Medical Building
San Francisco, CA 94158
Nurse Navigator for general questions
regarding making an appointment
New Patient Coordinator
University of California, San Francisco
Department of Urology, Mailcode 1695
550 16th Street, 6th Floor
San Francisco, CA 94143
aherlema Impact of the USPSTF 'D' recommendation on #prostatecancer screening and staging. @dr_coops @cgratzke t.co/22h20C32UF
dr_coops @writeo yep. See the Kelly et all @EUplatinum paper referenced in the review
radiolobt Impact of the USPSTF 'D' recommendation on prostate cancer screening and staging. by @dr_coops #thankyou #D? t.co/Zv5fNp5JZj
daviesbj Latest immunotherapy trial from $args fails in mRCC - tough space to attack t.co/N6uGqwDdbi
dr_coops @shaktifiedOm The short story is it means we're 94.7% sure the drug was effective. But anything <95% is considered failure...
dr_coops Contamination of PSA screening trial control groups had important impacts even in ERSPC t.co/Jwv8w1P3BB #pcsm
dr_coops This is a disgrace. And in Northern California no less. Remarkable bravery for telling your story! I just downloade… t.co/Zq7IL6Pt8W
dr_coops @sginzbu @tanejauro totally disagree. Even high quality MRI has real false neg rate. Low quality MRI to r/o biopsy is dangerous.
dr_coops @jambor_ivan @daviesbj @tanejauro @p_blancha @TurkuUroOnc show me that a community radiologist can do it reliably, and for <US$500
dr_coops @daviesbj @tanejauro @p_blancha Only organization is ACR. Which already gets truckloads of $ for crappy scans & had no incentive to improve.